- Home
- EPSM vs ADIL Comparison
EPSM vs ADIL Comparison
Compare EPSM & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | ADIL |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EPSM | ADIL |
|---|---|---|
| Price | $1.57 | $4.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 726.7K | 46.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $0.13 |
| 52 Week High | $42.45 | $7.20 |
Technical Indicators
Market Signals| Indicator | EPSM | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 38.28 |
| Support Level | $1.33 | $3.84 |
| Resistance Level | $1.59 | $5.08 |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 50.14 | 1.96 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.